X

On July 3, 2020 Sanofi Genzyme was notified that our Lemtrada Home Phlebotomy Partner, Examination Management Services Inc., (EMSI) has gone out of business. Because of this, unfortunately, all future Lemtrada Home Phlebotomy (lab draw) visits from EMSI have been cancelled. Patient safety is Sanofi Genzyme’s #1 priority and we are working to provide an alternative phlebotomy solution as well as coordinate alternative testing options for your next monthly lab tests. If you have any questions related to this announcement, please contact your healthcare provider or your One to One Nurse at 1-855-557-2483.

MAT-US-2015317

LEMTRADA is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Since treatment with LEMTRADA can increase your risk of getting certain conditions and diseases, LEMTRADA is generally prescribed for people who have tried 2 or more MS medicines that have not worked well enough. LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS). It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.

LEMTRADA is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Since treatment with LEMTRADA can increase your risk of getting certain conditions and diseases, LEMTRADA is generally prescribed for people who have tried 2 or more MS medicines that have not worked well enough. LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS). It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.

LEMTRADA study results

CLINICAL STUDIES

LEMTRADA was studied in 2 two-year clinical trials, and many LEMTRADA-treated patients were invited to continue in an extension study for an additional four years, for a total of 6 years. Read about the results here.

LEARN MORE


LEMTRADA dosing and administration information

HOW LEMTRADA IS GIVEN

LEMTRADA is given in two rounds of treatment, 12 months apart. Additional rounds of treatment may be given as needed.

SEE DOSING


LEMTRADA side effects and safety information

SAFETY AND SIDE EFFECTS

There are potential infusion reactions and serious side effects when taking LEMTRADA. Get the facts here.

SEE SAFETY


Post-infusion monitoring program

MONITORING PROGRAM

Monthly monitoring for 4 years after your last LEMTRADA infusion is an important part of your treatment plan. Find out why.

UNDERSTAND MONITORING


Relapsing MS doctor discussion guide download

HEALTHCARE PROVIDER
DISCUSSION GUIDE

Download this guide to prepare for a conversation about treatment.

Danielle
LEMTRADA
PATIENT

Being
impatient,

I wasn’t going
to wait
around.

See what led to Danielle’s decision to speak up for herself.

LEMTRADA study data

THE LEMTRADA
CLINICAL STUDIES

See how LEMTRADA was studied to assess relapses and disability.

Important Safety Information See More

LEMTRADA can cause serious side effects including serious autoimmune problems. Some people receiving LEMTRADA develop a condition where the immune cells in your body attack other cells or organs in the body (autoimmunity), which can be serious and may cause death. Serious autoimmune problems may include: